Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Voyageur Pharmaceuticals Ltd (OP: VYYRF )

0.0500 UNCHANGED
Last Price Updated: 3:46 PM EDT, Oct 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Voyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals "sees a gap in the market" for domestically-produced barium
Proactive Research Analyst Daniel Appiah speaks to Thomas Warner from the Londons studio after publishing a new research note on Canadian medical imaging contrast media company Voyageur Pharmaceuticals... 
Via TheNewswire.com
Voyageur Pharmaceuticals with a "big market to go for"
Proactive research analyst John Savin speaks to Thomas Warner after publishing a new research note on Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF), a Canadian company that specialises in... 
Via TheNewswire.com
Voyageur Pharmaceuticals Partners with Rain Cage Carbon to Revolutionize Medical Imaging with Nanocarbon-Based Contrast Drugs
Via TheNewswire.com
Voyageur Pharmaceuticals Ltd. Announces Update To PEA and a Related New Opportunity To Market High Purity USP Barium Sulfate
Calgary, Alberta - TheNewswire - August 19, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") has been working with SGS Canada Inc. on the Preliminary Economic... 
Via TheNewswire.com
Voyageur Pharmaceuticals Announces Board of Director Changes and 2nd quarter Financial Results
Calgary, Alberta - TheNewswire - July 26th, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the “Company” or “Voyageur”). Voyageur is very pleased to announce that Frank Wright and Ralph... 
Via TheNewswire.com
Voyageur Pharmaceuticals Ltd. Announces Completion of Private Placement
Calgary, Alberta - TheNewswire - June 14, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") announces that, further to news releases dated April 13 and 23, and... 
Via TheNewswire.com
Exposures Product Safety
Voyageur Pharmaceuticals Ltd. Issuance of 5th Product License for MultiXThick Radiographic Barium Contrast
Via Get News
Voyageur Pharmaceuticals Ltd. Announces Closing of Second Tranche of Private Placement
Calgary, Alberta – TheNewswire - May 28, 2021 – Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC:VYYRF) (the "Company" or "Voyageur") announces that, further to news releases dated April 13 and 23, 2021... 
Via TheNewswire.com
Voyageur Pharmaceuticals Ltd. Announces Health Canada Approval and Issuance of 5th Product License for MultiXThick Radiographic Barium Contrast
Calgary, Alberta - TheNewswire - May 17, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada... 
Via TheNewswire.com
Exposures Product Safety
Voyageur Pharmaceuticals Ltd. Announces Health Canada Approval and Issuance of Product Licenses for MultiXThin Radiographic Barium Contrast
Calgary, Alberta - TheNewswire - May 5, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada... 
Via TheNewswire.com
Exposures Product Safety
Voyageur Pharmaceuticals Ltd. Issued 4th Health Canada License For Radiographic Barium Contrast Product
Via Get News
Recent Decision from DC Circuit Court Likely to Result in Less Cost and Faster Approvals for Voyageur Barium Products - Voyageur Hires Team of Experts to Support Product Roll-Out
Calgary, Alberta – TheNewswire - April 20, 2021 – Voyageur Pharmaceuticals Ltd. (TSX.V:VM) USA (OTC:VYYRF) (the “Company” or “Voyageur”), is pleased to announce that the D.C. Circuit Court of Appeals 
Via TheNewswire.com
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.